We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 361

Intellectual Property Weekly Abstracts Bulletin Week of July 17, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • July 19 2017

In this case, AbbVie brought an application against Samsung pursuant to the NOC Regulations. The parties agreed that a protective order was needed


Intellectual Property Weekly Abstracts Bulletin Week of July 3, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • July 5 2017

Supreme Court of Canada invalidates the promise doctrine AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36 Drug: esomeprazole In this decision, the


Dismissed Motion for Interlocutory Injunction Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

This was an appeal against Justice Manson's unreported decision in 2016 FC 606, dismissing TearLab's motion for an interlocutory injunction to prevent


Leave to appeal dismissed where, inter alia, "conflicting" decisions regarding the issues in play were not from Ontario
  • Borden Ladner Gervais LLP
  • Canada
  • November 23 2016

The Ontario Court dismissed Pfizer's motion for leave to appeal from the decision dismissing its motion to strike out various claims, made by Apotex


Federal Court Reissues its Original Decision to Award Section 8 Damages After the Federal Court of Appeal Held the Original Decision Relied on Inadmissible Hearsay Evidence
  • Borden Ladner Gervais LLP
  • Canada
  • June 7 2017

The Federal Court has reaffirmed and reissued its original decision awarding section 8 damages to Teva following a redetermination that was ordered by


Court dismisses motion for Confidentiality Order
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2017

The Court dismissed Teva's motion for a confidentiality order. The underlying proceeding is an action by Teva to recover from Janssen and others


Court grants motion to reopen trial and admit new evidence
  • Borden Ladner Gervais LLP
  • Canada
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued


Compound patent held to be not soundly predicted for the level of promised utility found by the Court
  • Borden Ladner Gervais LLP
  • Canada
  • February 24 2016

The Federal Court has dismissed an application for prohibition concerning the drug ALIMTA. Although the parties joined issue on a significant number


Order of prohibition dismissed in respect of two patents listed against dasatinib
  • Borden Ladner Gervais LLP
  • Canada
  • April 6 2017

The Court dismissed Bristol Myers Squibb's application for an order prohibiting the Minister from issuing an NOC to Apotex for its generic version of


Dismissal of Motion to Vary Trial Decision in S. 8 case due to Later Infringement Finding Upheld on Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • July 27 2016

AstraZeneca has appealed a decision on its motion seeking to vary a judgment in a decision on the merits of a section 8 case. Damages were awarded to